Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29809882 | 0.75 | EGFR (0.46) | EGFR | |
| SCHEMBL140301 | 0.75 | EGFR (0.46) | EGFR | |
| SCHEMBL4424448 | 0.74 | EGFR (0.43) | EGFR | |
| SCHEMBL3625197 | 0.68 | — | — | |
| SCHEMBL35252 | 0.68 | LMNA (0.38) | — | |
| SCHEMBL3233384 | 0.68 | EGFR (0.38) | EGFR | |
| SCHEMBL3933701 | 0.67 | PI4KA (0.42) | EGFR | |
| SCHEMBL7738438 | 0.66 | EGFR (0.36) | EGFR | |
| SCHEMBL3938609 | 0.65 | — | — | |
| SCHEMBL7738436 | 0.65 | EGFR (0.35) | EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 662 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024106781-A1 | LIPID COMPOUND AND COMPOSITION FOR DELIVERY OF ACTIVE SUBSTANCE | 한국생명공학연구원 | 2024-05-23 | — | — | WO | claimed |
| US-20230357268-A1 | PREPARATION AND APPLICATION OF TRICYCLIC PYRIMIDINONE COMPOUND AND ITS COMPOSITION | NEUSCO BIOTECH LIMITED (CN) | 2023-11-09 | — | — | US | claimed |
| US-20230271980-A1 | PREPARATION AND APPLICATION OF TRICYCLIC PYRIMIDINONE COMPOUND AND ITS COMPOSITION | NEUSCO BIOTECH LIMITED (CN) | 2023-08-31 | — | — | US | claimed |
| US-20230242532-A1 | TETRACYCLIC PYRIMIDINONE COMPOUND, PREPARATION METHOD THEREFOR, AND COMPOSITION AND USE THEREOF | NEUSCO BIOTECH LIMITED (CN) | 2023-08-03 | — | — | US | claimed |
| US-20230212168-A1 | ENDOCYCLIC PYRIMIDINONE COMPOUNDS, AND PREPARATION METHODS, COMPOSITIONS AND USE THEREOF | NEUSCO BIOTECH LIMITED (CN) | 2023-07-06 | — | — | US | claimed |
| EP-4180436-A1 | TRICYCLIC PYRIMIDINONE COMPOUND, PREPARATION METHOD THEREFOR, AND COMPOSITION AND USE THEREOF | Neusco Biotech Limited (CN) | 2023-05-17 | — | — | EP | claimed |
| EP-4174070-A1 | TRICYCLIC PYRIMIDINONE COMPOUND, PREPARATION METHOD THEREFOR, AND COMPOSITION AND USE THEREOF | Neusco Biotech Limited (CN) | 2023-05-03 | — | — | EP | claimed |
| EP-4151638-A1 | BRIDGED CYCLIC PYRIMIDINONE COMPOUND, PREPARATION METHOD THEREFOR, COMPOSITION CONTAINING SAME AND USE THEREOF | Neusco Biotech Limited (CN) | 2023-03-22 | — | — | EP | claimed |
| WO-2022001881-A1 | TRICYCLIC PYRIMIDINONE COMPOUND, PREPARATION METHOD THEREFOR, AND COMPOSITION AND USE THEREOF | 上海纽思克生物科技有限公司 | 2022-01-06 | — | — | WO | claimed |
| WO-2021063145-A1 | TETRACYCLIC PYRIMIDINONE COMPOUND, PREPARATION METHOD THEREFOR, AND COMPOSITION AND USE THEREOF | 上海纽思克生物科技有限公司 | 2021-04-08 | — | — | WO | claimed |
| US-20040048903-A1 | Nicotinamide biaryl derivatives useful as inhibitors of PDE4 isozymes | PFIZER INC. | 2004-03-11 | — | — | US | claimed |
| US-20030186974-A1 | Pyrrolyl- and imidazolyl-acid amide derivatives useful as inhibitors of PDE4 isozymes | MARFAT ANTHONY (US) | 2003-10-02 | — | — | US | claimed |
| EP-1165566-B1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE AS INHIBITORS OF CYTOKINE MEDIATED DISEASE | ASTRAZENECA AB (SE) | 2003-08-20 | — | — | EP | claimed |
| US-20030130254-A1 | Oxazolyl-acid amide derivatives useful as inhibitors of PDE4 isozymes | MARFAT ANTHONY (US) | 2003-07-10 | — | — | US | claimed |
| US-6559168-B2 | 3',5'-cyclic nucleotide phosphodiesterases (PDEs); disease related to eosinophils, such as asthma, chronic bronchitis, and chronic obstructuive pulmonary disease | PFIZER INC | 2003-05-06 | — | — | US | claimed |
| US-20030027845-A1 | Ether derivatives useful as inhibitors of PDE4 isozymes | PFIZER INC. | 2003-02-06 | — | — | US | claimed |
| US-20020193612-A1 | Nicotinamide biaryl derivatives useful as inhibitors of PDE4 isozymes | PFIZER INC. | 2002-12-19 | — | — | US | claimed |
| US-20020123520-A1 | Thiazolyl-, oxazolyl-, pyrrolyl-, and imidazolyl-acid amide derivatives useful as inhibitors of PDE4 isozymes | PFIZER INC. | 2002-09-05 | — | — | US | claimed |
| US-20020111495-A1 | Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes | PFIZER INC. | 2002-08-15 | — | — | US | claimed |
| EP-1229034-A1 | Nicotinamide derivatives and their mimetics as inhibitors of PDE4 isozymes | Pfizer Products Inc. (US) | 2002-08-07 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130254-A1 | Oxazolyl-acid amide derivatives useful as inhibitors of PDE4 isozymes | CBR1, NOX1, NOX3 | EGFR 3675/4885 |
| US-20230212168-A1 | ENDOCYCLIC PYRIMIDINONE COMPOUNDS, AND PREPARATION METHODS, COMPOSITIONS AND USE THEREOF | PLA2G1B, PLA2G5, PLA2G4B | EGFR 2847/4885 |
| US-20020123520-A1 | Thiazolyl-, oxazolyl-, pyrrolyl-, and imidazolyl-acid amide derivatives useful as inhibitors of PDE4 isozymes | CBR1, CBR3, PDE4A | EGFR 3923/4885 |
| US-20020193612-A1 | Nicotinamide biaryl derivatives useful as inhibitors of PDE4 isozymes | CBR1, CBR3, NOX1 | EGFR 4517/4885 |
| US-20030186974-A1 | Pyrrolyl- and imidazolyl-acid amide derivatives useful as inhibitors of PDE4 isozymes | CBR1, PDE4A, PDE3B | EGFR 3996/4885 |
| US-20030027845-A1 | Ether derivatives useful as inhibitors of PDE4 isozymes | CBR1, PDE4A, PDE4B | EGFR 4256/4885 |
| US-20230242532-A1 | TETRACYCLIC PYRIMIDINONE COMPOUND, PREPARATION METHOD THEREFOR, AND COMPOSITION AND USE THEREOF | PLA2G1B, PLA2G5, PLA2G7 | EGFR 4426/4885 |
| US-20230271980-A1 | PREPARATION AND APPLICATION OF TRICYCLIC PYRIMIDINONE COMPOUND AND ITS COMPOSITION | PLA2G1B, PLA2G4B, PLA2G4A | EGFR 4299/4885 |
| US-20020111495-A1 | Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes | NOX3, NOX1, NOX4 | EGFR 4763/4885 |
| US-20040048903-A1 | Nicotinamide biaryl derivatives useful as inhibitors of PDE4 isozymes | CBR1, CBR3, NOX1 | EGFR 4551/4885 |
| US-20230357268-A1 | PREPARATION AND APPLICATION OF TRICYCLIC PYRIMIDINONE COMPOUND AND ITS COMPOSITION | PLA2G1B, PLA2G4B, PLA2G5 | EGFR 4391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.